A recent analysis reveals that a significant policy shift during the Trump administration has adversely affected the funding landscape for early-stage investigators at the National Institutes of Health (NIH). According to newly released data, the success rate for these researchers applying for R01 grants has dramatically decreased.
In the 2025 fiscal year, only 18.5% of early-career researchers successfully secured R01 funding, marking an alarming decline of 11 percentage points from the 29.8% success rate observed in 2023. This trend is particularly concerning as it reflects broader challenges within the NIH funding ecosystem, which has historically supported innovation and research advancement.
The data was presented during a recent advisory council meeting of the National Heart, Lung, and Blood Institute (NHLBI), where it was noted that the institute’s success rate for early-stage investigators also fell from approximately 31% to 21% during the same period. This decline may have significant implications for the future of biomedical research, potentially stifling the influx of new ideas and talent in the field.
Open the full market picture for your next decision →
